Jane Wasman is a strategic leader with approximately 25 years of experience in the biopharma industry working with companies ranging from large, multinational corporations to privately held start-ups. Ms. Wasman is a director and prior chair of the board of Sellas Life Sciences, a public oncology focused biotech company, as well as chair of its Nominations & Governance Committee. She also is a member of the board of directors and chair of the Nominations & Governance Committee of Rigel Pharmaceuticals, a public hematology/oncology company.  Previously, she was chair of the board of directors of Athersys, as well as chair of its Audit Committee, a member of the board of directors for Cytovia Therapeutics, and a member of the board and board executive committee of NewYorkBIO. Ms. Wasman is the founder and president of JWasman Advisors, a consulting firm focused on strategic, operational and corporate governance matters for biopharma and life sciences organizations. She previously was part of the management team at Acorda Therapeutics, a biotechnology company developing and commercializing neurology therapies for Parkinson’s disease, migraine and multiple sclerosis, most recently as President, International & General Counsel. At Acorda, she led global strategic development, including long range planning and development, as well as international expansion, and built and led the Legal and Quality departments. Prior to joining Acorda, Ms. Wasman held various leadership positions at Schering-Plough, including Staff Vice President and Associate General Counsel. Previously, Ms. Wasman was an attorney at two global law firms and Associate Counsel for the U.S. Senate Veterans’ Affairs Committee. Ms. Wasman graduated magna cum laude from Princeton University and earned her J.D. from Harvard Law School.